The X Waiver to Prescribe Buprenorphine: The Why and How

Affiliations

¹ William F. Connell School of Nursing, Boston College, Chestnut Hill, Massachusetts, USA.
² Division of Palliative Medicine, University of California San Francisco, San Francisco, California, USA.
³ Section of Palliative Care and Medical Ethics, Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
⁴ Program of Addiction Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
⁵ Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
⁶ Palliative Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

Editorial

Katie Fitzgerald Jones et al. J Palliat Med. 2022 Jul.

. 2022 Jul;25(7):1021-1023.

doi: 10.1089/jpm.2022.0170.

¹ William F. Connell School of Nursing, Boston College, Chestnut Hill, Massachusetts, USA.
² Division of Palliative Medicine, University of California San Francisco, San Francisco, California, USA.
³ Section of Palliative Care and Medical Ethics, Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
⁴ Program of Addiction Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
⁵ Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
⁶ Palliative Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

No abstract available

Publication types